言語を選択

HLA-A*0301 & B2M & gp100 (ALLAVGATK)

お問い合わせ

HLA-A*0301 & B2M & gp100 (ALLAVGATK)バックグランド

Glycoprotein 100, is also well known as gp100 and Melanocyte protein PMEL. This antigen is a melanocyte-specific type I transmembrane glycoprotein and composed of 661 amino acids. Glycoprotein 100 is related to the tumor regression in metastatic melanoma patients after adoptive therapy, by which its epitopes being recognized by tumor lymphocytes and T-cells. The gp100280–288(YLEPGPVTA) was originally shown to be recognized by HLA-A*0301 tumor-infiltrating lymphocytes from melanoma patients, and therefore it is widely been studied in TCR -T studies. The Human HLA-A*0301 gp100 (YLEPGPVTA) complex protein is a complex of HLA-A*0301 of the MHC Class I, B2M and YLEPGPVTA peptide of the gp100.

治験薬に関する情報

英語名	研究コード	研究開発ステージ	会社	適応症	臨床試験
PRT-001	PRT-001	Phase 3 Clinical	Particle Therapeutics	Hypoglycemia	詳細
Retatrutide	LY-3437943	Phase 3 Clinical	Eli Lilly And Company	Diabetes Mellitus, Type 2; Atherosclerosis; Renal Insufficiency; Sleep Apnea, Obstructive; Hepatic Insufficiency; Osteoarthritis, Knee; Cardiovascular Diseases; Renal Insufficiency, Chronic; Obesity; Overweight	詳細
Survodutide	BI-456906; BI-456909	Phase 3 Clinical	Zealand Pharma A/S	Metabolic Dysfunction-Associated Steatotic Liver Disease; Diabetes Mellitus, Type 2; Renal Insufficiency; Liver Cirrhosis; Fibrosis; Hepatitis; Liver Diseases; Obesity; Overweight; Diabetes Mellitus	詳細
Pemvidutide	ALT-801(Altimmune); SP-1373; VPD-107	Phase 2 Clinical	Velocity Pharmaceutical Development	Metabolic Dysfunction-Associated Steatotic Liver Disease; Diabetes Mellitus, Type 2; Obesity; Overweight	詳細
Efinopegdutide	JNJ-64565111; HM-12525A; JNJ-5111; MK-6024	Phase 2 Clinical	Hanmi Pharmaceutical Co Ltd	Metabolic Dysfunction-Associated Steatotic Liver Disease; Diabetes Mellitus, Type 2; Liver Diseases; Hepatic Insufficiency; Obesity; Kidney Failure, Chronic	詳細
Efocipegtrutide	HM-15211	Phase 2 Clinical	Hanmi Pharmaceutical Co Ltd	Metabolic Dysfunction-Associated Steatotic Liver Disease; Obesity	詳細
volagidemab	AMG-477; REMD-477	Phase 2 Clinical	Amgen Inc	Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Glucose Intolerance; Insulin Resistance; Hyperglycemia; Diabetes Mellitus	詳細
Isosteviol	ISV; STX-03	Phase 2 Clinical	Stevia Pharma	Diabetes Mellitus, Type 2	詳細
Oxyntomodulin long-acting (Pharmsynthez/Xenetic Biosciences)		Phase 2 Clinical	Pharmsynthez, Xenetic Biosciences Inc	Diabetes Mellitus, Type 2; Obesity	詳細
Pegapamodutide	WG4ID2U7FT; TT-401; LY-2944876; OPK-88003	Phase 2 Clinical	Eli Lilly And Company	Diabetes Mellitus, Type 2; Obesity	詳細
IONIS-GCGRRx	IONIS-GCGRRx; ISIS-449884; ISISGCGRRx	Phase 2 Clinical	Ionis Pharmaceuticals Inc	Diabetes Mellitus, Type 2	詳細
Efpegerglucagon	HM-15136	Phase 2 Clinical	Hanmi Pharmaceutical Co Ltd	Congenital Hyperinsulinism; Diabetes Mellitus, Type 2	詳細
AZD9550	AZD9550; AZD-9550	Phase 2 Clinical	Astrazeneca Plc	Metabolic Dysfunction-Associated Steatotic Liver Disease	詳細
MWN-101	MWN-101	Phase 2 Clinical	Shanghai Minwei Biotechnology Co Ltd	Diabetes Mellitus, Type 2; Obesity; Overweight	詳細
RBD-4988	RBD-4988	Phase 2 Clinical	Suzhou Ribo Life Science Co Ltd	Diabetes Mellitus, Type 2	詳細
PB-718	PB-718	Phase 2 Clinical	Peg Bio Co Ltd	Congenital Hyperinsulinism; Metabolic Dysfunction-Associated Steatotic Liver Disease; Obesity; Overweight	詳細
DD-01	DD-01	Phase 2 Clinical	D&D Pharmatech	Metabolic Dysfunction-Associated Steatotic Liver Disease; Diabetes Mellitus, Type 2; Obesity; Overweight	詳細
Cotadutide	MEDI-0382	Phase 2 Clinical	Medimmune Llc	Diabetes Mellitus, Type 2; Metabolic Dysfunction-Associated Steatotic Liver Disease; Renal Insufficiency; Liver Cirrhosis; Hepatic Insufficiency; Diabetic Nephropathies; Renal Insufficiency, Chronic; Obesity; Diabetes Mellitus	詳細
NN-9277	NN-9277; NNC-9204-1177	Phase 1 Clinical	Novo Nordisk A/S	Obesity; Overweight; Nutritional and Metabolic Diseases	詳細
Glucagon (rDNA origin, Lilly)		Phase 1 Clinical	Eli Lilly And Company	Diabetes Mellitus, Type 1; Hypoglycemia; Insulin Resistance; Obesity	詳細
Glucagon (Translational Research Institute for Metabolism and Diabetes, Florida)		Phase 1 Clinical	Translational Research Institute For Metabolism And Diabetes	Obesity	詳細
NNC-92041706	NNC9204-1706; NNC-92041706; NN-9423; NNC-92041706-A	Phase 1 Clinical	Novo Nordisk A/S	Obesity; Nutritional and Metabolic Diseases	詳細
PRT-003	PRT-003	Phase 1 Clinical	Particle Therapeutics		詳細
SAR-441255	SAR-441255	Phase 1 Clinical	Sanofi	Overweight	詳細
Glucagon/insulin human(Abvance Therapeutics)	ABV-100	Phase 1 Clinical	Abvance Therapeutics	Hypoglycemia	詳細
PB-722	PB722; PB-722	Phase 1 Clinical	Peg Bio Co Ltd	Congenital Hyperinsulinism	詳細
UBT-251	UBT-251; UBT251	Phase 1 Clinical	Lianbang Biotechnology (Zhuhai Hengqin) Co Ltd	Metabolic Dysfunction-Associated Steatotic Liver Disease; Diabetes Mellitus, Type 2; Obesity; Overweight	詳細
TY-751	TY-751; TY751	Phase 1 Clinical		Metabolic Dysfunction-Associated Steatotic Liver Disease; Diabetes Mellitus, Type 2; Obesity; Diabetes Mellitus	詳細
DA-1726	DA-1726	Phase 1 Clinical	Dong-A ST Co Ltd	Metabolic Dysfunction-Associated Steatotic Liver Disease; Obesity	詳細
ZX-2021	ZX2021; ZX-2021	Phase 1 Clinical	Jiangsu Zhongxin Pharmaceutical Co Ltd	Diabetes Mellitus, Type 2; Obesity; Overweight	詳細
DR-10624	DR-10624	Phase 1 Clinical	Zhejiang Doer Biologics Corp	Hypertriglyceridemia; Diabetes Mellitus, Type 2; Metabolic Dysfunction-Associated Steatotic Liver Disease; Metabolic Syndrome; Obesity; Overweight; Diabetes Mellitus	詳細
TB-001	TB-001; TB001	Phase 1 Clinical	Shenzhen Tuwei Anchuang Technology Development Co Ltd	Metabolic Dysfunction-Associated Steatotic Liver Disease; Liver Cirrhosis	詳細
Human glucagon(Shanghai Duomirui)		Phase 1 Clinical	Shanghai Duomirui Biotechnology Co Ltd	Hypoglycemia	詳細

市販薬剤に関する情報

英語名	研究コード	研究開発ステージ	会社	オリジナル製品名	最初に承認をした国	最初の適応症	最初に承認を受けた会社	承認された日付	適応症	臨床試験
Glucagon (rDNA origin, Novo Nordisk)	GL-G	Approved	Novo Nordisk A/S	GlucaGen, Glucagon G	United States	Gastrointestinal Diseases; Hypoglycemia	Novo Nordisk A/S	1998-06-22	Diabetes Mellitus, Type 1; Gastrointestinal Diseases; Hypoglycemia; Obesity	詳細
Dasiglucagon	ZP-GA-1; ZP-4207	Approved	Zealand Pharma A/S	Zegalogue	United States	Hypoglycemia	Zealand Pharma Us Inc	2021-03-22	Diabetes Mellitus, Type 1; Congenital Hyperinsulinism; Hypoglycemia; Glucose Metabolism Disorders; Hyperinsulinism	詳細
Glucagon	MP-123456B	Approved	Eli Lilly And Company	Ogluo, Baqsimi	EU	Hypoglycemia	Eli Lilly Nederland BV	1960-11-14	Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Hypoglycemia	詳細
Glucagon intranasal (Eli Lilly/Locemia Solutions)	AMG504-1; LY-900018	Approved	Amg Medical, Locemia Solutions						Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Hypoglycemia; Diabetes Mellitus	詳細
Glucagon (Xeris Pharmaceuticals)		Approved	Xeris Pharmaceuticals Inc	Gvoke	United States	Hypoglycemia	null	1960-01-01	Hypoglycemia; Hyperinsulinism	詳細